Teva plans to take over major chunk of migraine market

Teva turns up its ambitions for migraine drug Ajovy, which is taking over a larger part of the US market than initially stated.

Teva CEO Kåre Schultz | Photo: Amir Cohen/REUTERS / X02077

In future years, more US patients will start treatment with Teva's migraine drug Ajovy.

According to Danish newspaper Børsen, Teva's new goal is that the drug, which competes with other drugs such as Danish firm Lundbeck's Vyepti, will reach a 33 percent market share in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs